Background: Fat grafting has been demonstrated as a means of reconstructing breast conservation therapy defects. However, there is continued uncertainty regarding its clinical efficacy and oncologic safety. Furthermore, the role of external preexpansion (i.e., with the Brava device) remains unclear in this setting. The purpose of this study was to examine the safety and clinical outcomes of Brava/fat grafting following breast conservation therapy.
Methods: A retrospective chart review was performed on all patients undergoing fat grafting following breast conservation therapy. Complications were defined as either a clinically palpable oil cyst/area of fat necrosis or infection. The mean time of follow-up was 2.3 years.
Results: A total of 27 fat grafting sessions were performed on 20 patients, with an overall complication rate of 25 percent. The mean interval from completion of radiation therapy to fat grafting was 7 years and was not a significant predictor for complications (p = 0.46). Among those who underwent repeated grafting, there was no difference in the complication rates between their first and second encounters (p = 0.56). There was no difference in complication rates between patients with Brava preexpansion and those without preexpansion. Patients undergoing Brava preexpansion had a significantly higher initial fill volume in comparison with those who did not (219 cc versus 51 cc; p = 0.0017). There were no cases of locoregional cancer recurrence following fat grafting.
Conclusion: Brava preexpansion was associated with higher initial fill volume in the setting of breast conservation therapy defects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PRS.0000000000003626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Radiotherapy on the Type and Timing of Breast Reconstruction After Mastectomy in Breast Cancer Patients.
Sisli Etfal Hastan Tip Bul
December 2024
Department of Plastic and Reconstructive Surgery, Memorial Hospital, Istanbul, Türkiye.
Breast cancer is the most common cancer type among women according to the World Health Organization data. While breast-conserving surgery has been increasingly performed in patients with early-stage breast cancer, unilateral or bilateral mastectomy is still performed in many patients. With the changes in mastectomy techniques and the development of breast reconstruction techniques over the years, today the aim of breast reconstruction is to create breast tissue in a shape and symmetry that will correct the anatomical defect that occurs after mastectomy, without affecting the patient's oncological treatment.
View Article and Find Full Text PDFAssessing fetal radiation dose from iodine-125 seeds in pregnant breast cancer patients: an updated model.
Phys Med Biol
January 2025
Department of Medical Physics, Jeroen Bosch Ziekenhuis, Henri Dunantstraat 1, 's-Hertogenbosch, 5223GZ, NETHERLANDS.
The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure.
View Article and Find Full Text PDFXenogeneic platelet-rich plasma lotion for preventing acute radiation dermatitis in patients with breast cancer undergoing radiotherapy: An open-label, randomized controlled trial.
JPRAS Open
March 2025
Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Background: Breast cancer patients experience acute radiation dermatitis (ARD) during radiation therapy (RT). This study investigated the prophylactic effect of a newly developed xenogeneic platelet-rich plasma (PRP) lotion on ARD for breast cancer patients.
Methods: This study enrolled patients with ductal carcinoma in situ and early-stage invasive breast cancers after breast-conserving surgery.
Transferrin Disassociates TCR from CD3 Signaling Apparatus to Promote Metastasis.
Research (Wash D C)
January 2025
Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, Sino-African Joint Research Center, and New Cornerstone Science Laboratory, Kunming Institute of Zoology, The Chinese Academy of Sciences, Kunming, Yunnan 650201, China.
Immune recognition and activation by the peptide-laden major histocompatibility complex-T cell receptor (TCR)-CD3 complex is essential for anti-tumor immunity. Tumors may escape immune surveillance by dissembling the complex. Here, we report that transferrin, which is overexpressed in patients with liver metastasis, disassociates TCR from the CD3 signaling apparatus by targeting the constant domain (CD) of T cell receptor α (TCRα), consequently suppresses T cell activation, and inhibits anti-metastatic and anti-tumor immunity.
View Article and Find Full Text PDFBreast Conservation Surgery for Breast Cancer in Men.
J Am Coll Surg
January 2025
The University of Texas Medical Branch at Galveston, Department of Surgery.
Background: Male breast cancer (MBC) is a rare disease, accounting for 1% of all breast cancers diagnosed in the United States. The rarity of MBC has limited the development of treatment algorithms specific to men. Thus, the standard of care has been mastectomy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!